Immobilized human LAG-3 at 0.5 μg/ml (50 μL/well) can bind to Relatlimab with a linear range of 1.221 ng/ml-5 μg/ml.
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | LAG-3 |
| Synonyms | Lymphocyte activation gene 3 protein, CD223, FDC |
| Accession | P18627 |
| Clone Number | S-SC019 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG4,k |
| Application | Blocking of LAG-3 signaling Functional assays |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ELISA | 1.221-5000 ng/ml |
Background
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. It is used in combination with nivolumab to treat melanoma.
Picture
Picture
ELISA
